The effects of agomelatine on endoplasmic reticulum stress related to mitochondrial dysfunction in hippocampus of aging rat model

Chem Biol Interact. 2022 Jan 5:351:109703. doi: 10.1016/j.cbi.2021.109703. Epub 2021 Oct 19.

Abstract

Background: Agomelatine, a novel antidepressant, is a melatonin MT receptor agonist and serotonin 5HT2C receptor antagonist. In this study, agomelatine was used to investigate the molecular mechanisms of hippocampal aging associated with endoplasmic reticulum (ER) stress, mitochondrial dysfunction, and apoptosis, all of which led to short-term memory impairment.

Method: Hippocampal aging was induced in male Wistar rats by d-galactose (D-gal) intraperitoneal injection (100 mg/kg) for 14 weeks. During the last 4 weeks of D-gal treatment, rats were treated with agomelatine (40 mg/kg) or melatonin (10 mg/kg). At the end of the experiment, all rats were assessed for short-term memory by using the Morris water maze test. Subsequently, rats were sacrified and the hippocampus was removed from each rat for determination of reactive oxygen species (ROS), malondialdehyde (MDA), and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays; and immunohistochemistry related to ER stress, mitochondrial dysfunction, and apoptosis.

Results: Agomelatine suppressed the expression of the aging-related proteins P16 and receptor for advanced glycation endproducts (RAGE), the expression of NADPH oxidase (NOX) 2 and 4, and ROS production. This treatment also shifted the morphology of astrocytes and microglia toward homeostasis. Furthermore, agomelatine decreased inositol-requiring enzyme 1 (pIRE1), protein kinase R-like endoplasmic reticulum kinase (pPERK), and chaperone binding immunoglobulin protein (BiP), leading to suppression of ER stress markers C/EBP homologous protein (CHOP) and caspase-12. Agomelatine reduced Ca2+ from the ER and stabilized the mitochondrial membrane stability, which was denoted by the BCL2 Associated X (Bax)/B-cell lymphoma 2 (Bcl2) balance. Agomelatine decreased cleaved caspase-3 production and the Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL)-positive area, and glutamate excitotoxicity was prevented via suppression of N-methyl-d-aspartate (NMDA) receptor subunit expression. Agomelatine exhibited effects that were similar to melatonin.

Conclusion: Agomelatine improved neurodegeneration in a rat model of hippocampal aging by attenuating ROS production, ER stress, mitochondrial dysfunction, excitotoxicity, and apoptosis.

Keywords: Agomelatine; ER stress; Hippocampal aging; Melatonin; d-galactose.

MeSH terms

  • Acetamides / therapeutic use*
  • Aging / drug effects
  • Animals
  • Apoptosis / drug effects
  • Calcium / metabolism
  • Endoplasmic Reticulum Stress / drug effects*
  • Galactose
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Memory, Short-Term / drug effects
  • Mitochondria / drug effects*
  • Neurodegenerative Diseases / chemically induced
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / metabolism
  • Neurons / drug effects
  • Neuroprotective Agents / therapeutic use*
  • Rats
  • Rats, Wistar
  • Receptor for Advanced Glycation End Products / metabolism
  • Receptor, Melatonin, MT1 / agonists

Substances

  • Acetamides
  • Ager protein, rat
  • Neuroprotective Agents
  • Receptor for Advanced Glycation End Products
  • Receptor, Melatonin, MT1
  • agomelatine
  • Matrix Metalloproteinase 9
  • Mmp9 protein, rat
  • Calcium
  • Galactose